Franklin Genomic Advancements ETF (HELX) is currently trading at $43.05. You can also track daily change, historical performance, trading volume and other key ETF details on this page.

Indian investors can buy Franklin Genomic Advancements ETF (HELX) by opening a US investing account through a platform that provides access to US stocks and ETFs, completing the required verification, transferring funds under the Liberalised Remittance Scheme (LRS), and placing an order in USD.

Yes, Indian residents and NRIs can invest in Franklin Genomic Advancements ETF (HELX) through platforms that offer access to US-listed stocks and ETFs, subject to applicable regulations, including RBI’s Liberalised Remittance Scheme (LRS) guidelines.

The expense ratio of Franklin Genomic Advancements ETF (HELX) is 0.5%. It represents the annual operating cost charged by the ETF provider for managing the fund and tracking its underlying index.

Franklin Genomic Advancements ETF (HELX)’s top holdings currently include Natera Inc, Guardant Health Inc, and Krystal Biotech Inc. The ETF’s complete holdings list, allocation and sector exposure are available in the Holdings section on this page.

Many platforms offering US ETF investing allow fractional investing, enabling Indian investors to buy a portion of Franklin Genomic Advancements ETF (HELX) instead of a full share. This allows investment based on a fixed dollar amount.

Gains from Franklin Genomic Advancements ETF (HELX) are generally taxed in India based on the applicable holding period and tax rules. Dividends may be subject to US withholding tax and Indian taxation rules. The final tax treatment depends on individual circumstances.

Remittances under the Liberalised Remittance Scheme (LRS) for overseas investments, including US ETFs like Franklin Genomic Advancements ETF (HELX), may attract TCS above specified thresholds. Applicable rates and limits are determined by government regulations and may change over time.

Franklin Genomic Advancements ETF (HELX)’s current assets under management (AUM) are $34.16M. AUM represents the total market value of assets managed by the ETF and indicates the size of the fund.

Franklin Genomic Advancements ETF (HELX)’s price-to-earnings (P/E) ratio is 27.38. It represents the weighted valuation of the companies held within the ETF relative to their earnings.

You can compare Franklin Genomic Advancements ETF (HELX) with Health Care Select Sector SPDR® Fund (XLV), Vanguard Health Care Index Fund ETF Shares (VHT), and iShares Biotechnology ETF (IBB) based on metrics such as expense ratio, AUM, P/E ratio, holdings, liquidity and historical returns in the Peers & Comparison section.

Franklin Genomic Advancements ETF (HELX)’s NAV represents the per-unit value of the ETF’s underlying holdings after adjusting for expenses and liabilities. It is calculated once daily after markets close and may differ from the ETF’s live market price.